Organisation paid for research Program year 2025 Source: CMS Open Payments

Beacon Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,511,632

300 payments

Through program year 2025, Beacon Clinical Research LLC is reported as receiving $1,511,632 in research payments, across 300 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$108,636	28
2024	Research	$456,875	61
2023	Research	$374,667	28
2022	Research	$48,220	34
2021	Research	$126,370	45
2020	Research	$220,767	49
2019	Research	$176,097	55

Breakdown

Who paid Research payments · program years 2019–2025

Vanda Pharmaceuticals Inc. $756,363 46 payments
AbbVie, Inc. $282,321 71 payments
LEO Pharma AS $170,840 27 payments
Eli Lilly and Company $98,553 13 payments
Teva Pharmaceuticals USA, Inc. $74,214 23 payments
Eisai Inc. $38,947 22 payments
Regeneron Pharmaceuticals, Inc. $29,402 74 payments
Pfizer Inc. $22,317 9 payments
Takeda Pharmaceuticals U.S.A., Inc. $21,798 6 payments
Dermira, Inc. $10,736 3 payments

Studies the money was for Research payments · program years 2019–2025

An Open Label Study to Investigate the Safety and Efficacy of Tradipitant in Participants Affected By Motion Sickness $439,700 23 payments
A Randomized Study Investigating the Efficacy of Tradipitant in Treating Motion Sickness $147,590 2 payments
Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend $117,838 17 payments
A Study to Investigate the Efficacy of Tradipitant in Subjects Affected By Motion Sickness $107,198 13 payments
M16-046 $81,885 8 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia $74,214 23 payments
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness $61,875 8 payments
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $56,760 10 payments
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $46,430 3 payments
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder $38,947 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.